Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

1.

Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences.

Huybrechts KF, Caro JJ, O'Brien JA.

Value Health. 2009 Jan-Feb;12(1):16-9. doi: 10.1111/j.1524-4733.2008.00408.x. Epub 2008 Jul 18.

PMID:
18647261
[PubMed - indexed for MEDLINE]
2.

Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.

Goldsmith DR, Scott LJ, Cvetković RS, Plosker GL.

Drugs. 2008;68(1):85-104. Review.

PMID:
18081374
[PubMed - indexed for MEDLINE]
3.

Ten-year experience with sevelamer and calcium salts as phosphate binders.

Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM.

Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S31-40. doi: 10.2215/CJN.05880809. Review.

PMID:
20089501
[PubMed - indexed for MEDLINE]
Free Article
4.

Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?

Negri AL.

J Nephrol. 2010 Nov-Dec;23(6):653-7. Review.

PMID:
20349415
[PubMed - indexed for MEDLINE]
Free Article
5.

The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.

Assimon MM, Mousa S, Shaker O, Pai AB.

Consult Pharm. 2010 Jan;25(1):41-54. doi: 10.4140/TCP.n.2010.41. Review.

PMID:
20211816
[PubMed - indexed for MEDLINE]
6.

Sevelamer carbonate.

Barna MM, Kapoian T, O'Mara NB.

Ann Pharmacother. 2010 Jan;44(1):127-34. doi: 10.1345/aph.1M291. Epub 2009 Dec 2. Review.

PMID:
19955298
[PubMed - indexed for MEDLINE]
7.

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.

Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18. Review.

PMID:
19692157
[PubMed - indexed for MEDLINE]
8.

Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis.

Nolan CR, Qunibi WY.

Kidney Int Suppl. 2005 Jun;(95):S13-20. Review.

PMID:
15882308
[PubMed - indexed for MEDLINE]
Free Article
9.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

PMID:
17999842
[PubMed - indexed for MEDLINE]
Free Article
10.

[Phosphorus (P) chelant in dialysis: efficacy and cost. Peritoneal dialysis solutions].

Montenegro J.

Nefrologia. 2008;28 Suppl 5:53-7. Review. Spanish.

PMID:
18847421
[PubMed - indexed for MEDLINE]
11.

Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.

Pai AB, Shepler BM.

Pharmacotherapy. 2009 May;29(5):554-61. doi: 10.1592/phco.29.5.554. Review.

PMID:
19397463
[PubMed - indexed for MEDLINE]
12.

[Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].

Koizumi M, Fukagawa M.

Clin Calcium. 2010 Nov;20(11):1700-8. doi: CliCa101117001708. Review. Japanese.

PMID:
21037391
[PubMed - indexed for MEDLINE]
13.

Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.

Nolan CR, Qunibi WY.

Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. Review.

PMID:
12815333
[PubMed - indexed for MEDLINE]
14.

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.

Sprague SM.

Curr Med Res Opin. 2007 Dec;23(12):3167-75. Review. Erratum in: Curr Med Res Opin. 2008 Mar;24(3):708.

PMID:
17991307
[PubMed - indexed for MEDLINE]
15.

Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.

Plosker GL, Lyseng-Williamson KA.

Pharmacoeconomics. 2007;25(12):1031-53. Review.

PMID:
18047388
[PubMed - indexed for MEDLINE]
16.

Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data.

Frazão JM, Adragão T.

Kidney Int Suppl. 2008 Dec;(111):S38-43. doi: 10.1038/ki.2008.544. Review.

PMID:
19034324
[PubMed - indexed for MEDLINE]
Free Article
17.

Nonphosphate-binding effects of sevelamer--are they of clinical relevance?

Marangon N, Lindholm B, Stenvinkel P.

Semin Dial. 2008 Sep-Oct;21(5):385-9. doi: 10.1111/j.1525-139X.2008.00440.x. Epub 2008 Jun 19. Review.

PMID:
18573137
[PubMed - indexed for MEDLINE]
18.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
19.

[Management of hyperphosphatemia ; phosphate-binder].

Yokoyama K.

Clin Calcium. 2009 Feb;19(2):205-12. doi: CliCa0902205212. Review. Japanese.

PMID:
19182360
[PubMed - indexed for MEDLINE]
20.

Oral phosphate binders for the management of serum phosphate levels in dialysis patients.

Mohammed I, Hutchison AJ.

J Ren Care. 2009 Mar;35 Suppl 1:65-70. doi: 10.1111/j.1755-6686.2009.00052.x. Review.

PMID:
19222734
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk